Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium (the tissue) and space around the alveoli (air sacs) of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. While many forms are progressive and serious, some types of ILD remain mild or stable for extended periods, especially with early detection and appropriate treatment. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases. There are specific types in children, known as children's interstitial lung diseases. The acronym ChILD is sometimes used for this group of diseases. In children, the pathophysiology involves a genetic component, exposure-related injury, autoimmune dysregulation, or all of the components.
== Interactions == Methamphetamine is metabolized by the liver enzyme CYP2D6, so CYP2D6 inhibitors will prolong the elimination half-life of methamphetamine. Methamphetamine also interacts with monoamine oxidase inhibitors (MAOIs), since both MAOIs and methamphetamine increase plasma catecholamines; therefore, concurrent use of both is dangerous. Methamphetamine may decrease the effects of sedatives and depressants and increase the effects of antidepressants and other stimulants as well. Methamphetamine may counteract the effects of antihypertensives and antipsychotics owing to its effects on the cardiovascular system and cognition respectively. The pH of gastrointestinal content and urine affects the absorption and excretion of methamphetamine. Specifically, acidic substances will reduce the absorption of methamphetamine and increase urinary excretion, while alkaline substances do the opposite. Owing to the effect pH has on absorption, proton pump inhibitors, which reduce gastric acid, are known to interact with methamphetamine. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans. Similarly, norepinephrine–dopamine reuptake inhibitors (NRIs) like methylphenidate and bupropion prevent norepinephrine and dopamine release induced by amphetamines and bupropion has been found to reduce the subjective and sympathomimetic effects of methamphetamine in humans.
=== 2011–2012: Early career === Hibberd was drafted by the Essendon Football Club with their only selection and fourth overall in the 2011 pre-season draft. He made his AFL debut in the 139-point win against Gold Coast at Etihad Stadium in round six. He was omitted the next week for the match against West Coast, before returning in round eight in the thirty-six point win against Brisbane at the Gabba, where he recorded twenty-two disposals and was praised by then-Essendon coach, James Hird, in particular for his courage around the ball. Playing the next seven matches, he missed the round seventeen match against Adelaide at AAMI Stadium due to a hamstring injury. After playing the first five matches for the 2012 season, he suffered a hamstring injury during the first quarter of the Anzac Day clash against Collingwood in round five, which forced him to miss six weeks of football. He made his return from injury through the Victorian Football League (VFL), playing for Essendon's affiliate team, Bendigo. After playing two matches in the VFL, he returned to the AFL side for the twenty-four point win against Fremantle at Patersons Stadium in round thirteen. He played the next three matches before injuring his quad in the fifty point win against Port Adelaide at AAMI Stadium in round sixteen. He missed three weeks due to the injury and returned to the side for the twenty-four point loss against North Melbourne at Etihad Stadium in round twenty.
Sources: en.wikipedia.org
Just as every individual derives from masculine and feminine genes, and the sex is determined by the predominance of the corresponding genes, so in the psyche it is only the conscious mind, in a man, that has the masculine sign, while the unconscious is by nature feminine. The reverse is true in the case of a woman. All I have done in my anima theory is to rediscover and reformulate this fact. It had long been known. Jung's position on biologically based sex differences in psychological orientation has become an issue of contention within contemporary Jungian and post-Jungian scholarship. For example, numerous scholars inspired by postmodernism and gender theory, have rejected this aspect of Jung's thinking as an expression of sexist and patriarchal stereotypes. Others have countered this position, arguing that Jung rejected a tabula rasa (blank slate) or social constructionist view of the human mind and sex differences, and that his theory of sex differences is supported by contemporary evolutionary theory, cross-cultural anthropological data and experimental psychology. As one author has commented, reflecting on this debate, the postmodern approach to sex and gender in post-Jungian scholarship 'goes against the grain of [Jung's] entire oeuvre…It is a betrayal of his legacy.'
=== Eastern Docks === Dover's Eastern Docks were used for ship breaking beginning during the First World War, when the Admiralty began dismantling ships there. The Stanlee Shipbreaking and Salvage Co. Ltd. took over the ship breaking operation commercially in 1920. Many of the ships broken up were naval vessels from the First World War. The company also handled machinery and general scrap, including the dismantling of the Dover Promenade Pier. The yard began to shrink after World War II and was closed in 1964 to make way for port redevelopment and a car ferry terminal. From 1930 until 1950 an aerial ropeway carried coal from Tilmanstone colliery, 7½ miles to the north. It emerged halfway up the Langdon cliffs directly above the Eastern harbour arm, through two portals which have been bricked up but can still be seen from the ferry port. Coal was deposited in bunkers at the outer end of the Eastern harbour arm. The ropeway had 600 1-ton buckets that departed at intervals of 21 seconds and travelled at 4½ miles per hour. The system could thus transport 120 tons of coal per hour.
No intraoperative or postoperative complications were reported, highlighting the procedure's safety profile. CAIRS keratoplasty is particularly advantageous for asymmetric or decentered cones, where customized segment shapes can be tailored to optimize corneal flattening and astigmatism correction. Subsequent studies have validated its efficacy in other types of corneal ectasia, with long-term stability observed up to 5 years. Soosan Jacob holds patents for specialized trephines and devices facilitating CAIRS implantation, further advancing its precision and reproducibility. The ability to customise CAIRS keratoplasty segments to achieve better vision for patients with irregular topography is a huge advantage of the procedure. Some companies have trademarked commercial names for pre-prepared commercial segments such as "CTAK". These procedures are still a CAIRS keratoplasty procedures but the provision of the tissue has been given a brand name for marketing and awareness purposes. An online surgical planning tool has been developed by keratoconus specialists from Brisbane in Australia, Dr Brendan Cronin and Dr David Gunn. This site www.cairsplan.com is free and provides surgeons a tool to assist in planning their CAIRS keratoplasty procedures to enhance outcomes.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.